How can germline mutations distinguish risk for lethal and indolent prostate cancer?
The promising potential of PARP inhibitors in ovarian cancer
The importance of the OlympiA trial for breast cancer patients
AURELIA: Phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
ESMO’s scientific value for gynecologic oncology
Mansoor Raza Mirza